Advertisement

Topics

Restriction of Radium-223 Dichloride Recommended in Europe

07:16 EDT 13 Jul 2018 | Medscape

Use of the novel radiopharmaceutical radium-223 dichloride (Xofigo, Bayer) in prostate cancer should be restricted, according to the European Medicines Agency.
News Alerts

Original Article: Restriction of Radium-223 Dichloride Recommended in Europe

NEXT ARTICLE

More From BioPortfolio on "Restriction of Radium-223 Dichloride Recommended in Europe"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...